Trial Profile
The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Iodine-131 (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Jan 2022 Planned number of patients changed from 40 to 42.
- 18 Jan 2022 Status changed from not yet recruiting to recruiting.
- 09 Aug 2021 Planned initiation date changed from 20 Jul 2021 to 15 Aug 2021.